Agency Forms Undergoing Paperwork Reduction Act Review, 71804-71806 [2015-29273]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
71804
Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices
Section C–B, Organization and
Functions, is hereby amended as
follows:
Delete in its entirety the title and
function statements for the Influenza
Coordination Unit (CVA4).
Delete in its entirety the title and
function statements for the National
Center for Immunization and
Respiratory Diseases (CVG) and insert
the following:
National Center for Immunization
and Respiratory Diseases (CVG). The
National Center for Immunization and
Respiratory Diseases (NCIRD) prevents
disease, disability, and death through
immunization and by control of
respiratory and related diseases. In
carrying out its mission, NCIRD: (1)
Provides leadership, expertise, and
service in laboratory and
epidemiological sciences, and in
immunization program delivery; (2)
conducts applied research on disease
prevention and control; (3) translates
research findings into public health
policies and practices; (4) provides
diagnostic and reference laboratory
services to relevant partners; (5)
conducts surveillance and research to
determine disease distribution,
determinants, and burden nationally
and internationally; (6) responds to
disease outbreaks domestically and
abroad; (7) ensures that public health
decisions are made objectively and
based upon the highest quality of
scientific data; (8) provides technical
expertise, education, and training to
domestic and international partners; (9)
provides leadership to internal and
external partners for establishing and
maintaining immunization, and other
prevention and control programs; (10)
develops, implements, and evaluates
domestic and international public
health policies; (11) communicates
information to increase awareness,
knowledge, and understanding of public
health issues domestically and
internationally, and to promote effective
immunization programs; (12) aligns the
national center focus with the overall
strategic goals of CDC; (13) synchronizes
all aspects of CDC’s pandemic influenza
preparedness and response from
strategy through implementation and
evaluation; and (14) implements,
coordinates, and evaluates programs
across NCIRD, Office of Infectious
Diseases (OID), and CDC to optimize
public health impact.
After the Office of Science and
Integrated Programs (CVG17) insert the
following:
Influenza Coordination Unit (CVG18).
The mission of the Influenza
Coordination Unit (ICU) is to
synchronize all aspects of CDC’s
VerDate Sep<11>2014
18:14 Nov 16, 2015
Jkt 238001
pandemic influenza preparedness and
response from strategy through
implementation and evaluation. In
carrying out its mission, the ICU: (1)
Serves as the principal advisor to the
CDC Director on pandemic influenza
preparedness and response activities,
assisting the Director in formulating and
communicating strategic pandemic
initiatives and policies; (2) provides
strategic leadership for CDC in the areas
of pandemic preparedness and
response, including setting priorities
and promoting science, policies, and
programs related to pandemic influenza;
(3) strategically manages a budget and
allocates funds across the agency to
ensure appropriate resources for high
priority areas; and (4) conducts ongoing
evaluation and adjustment of pandemic
preparedness and response activities, in
coordination with the National
Response Framework and other
emergency preparedness guidance, to
ensure optimal public health
effectiveness and efficient use of human
and fiscal resources by developing and
leading an exercise program for the
Agency, in collaboration with HHS and
other partners.
James Seligman,
Acting Chief Operating Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2015–29276 Filed 11–16–15; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors, Office
of Infectious Diseases: Notice of
Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the Board
of Scientific Counselors, Office of
Infectious Diseases, Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS), has been renewed for a
2-year period through October 31, 2017.
For information, contact Robin
Moseley, M.A.T., Designated Federal
Officer, Board of Scientific Counselors,
Office of Infectious Diseases, CDC, HHS,
1600 Clifton Road NE., Mailstop D10,
Atlanta, Georgia 30329–4027, telephone
404/639–4461 or fax 404/235–3562.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2015–29258 Filed 11–16–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–16–0964]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
E:\FR\FM\17NON1.SGM
17NON1
71805
Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Interventions to Reduce Shoulder
MSDS in Overhead Assembly (OMB No.
0920–0964 Exp. 04/30/2015)—
Reinstatement—National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The mission of the National Institute
for Occupational Safety and Health
(NIOSH) is to promote safety and health
at work for all people through research
and prevention. Under Public Law 91–
596, sections 20 and 22 (Section 20–22,
Occupational Safety and Health Act of
1970), NIOSH has the responsibility to
conduct research to advance the health
and safety of workers. In this capacity,
NIOSH proposes to conduct a study to
assess the effectiveness and cost-benefit
of occupational safety and health (OSH)
interventions to prevent
musculoskeletal disorders (MSDs)
among workers in the Manufacturing
(MNF) sector.
A reinstatement is necessary because
there were significant delays in
implementing the tooling intervention
in the intended work processes. These
delays were to a large degree due to
business conditions and were outside of
the control of investigators. As result,
the study achieved approximately 50%
of the original sample size approved by
OMB in the original ICR request. The
reinstatement is necessary to extend the
duration of the ICR so that the
additional participants can enrolled and
data collection can continue.
The U.S. Manufacturing sector has
faced a number of challenges including
an overall decline in jobs, an aging
workforce, and changes in
organizational management systems.
Studies have indicated that the average
age of industrial workers is increasing
and that older workers may differ from
younger workers in work capacity,
injury risk, severity of injuries, and
speed of recovery (Kenny et al., 2008;
Gall et al., 2004; Restrepo et al., 2006).
As the average age of the industrial
population increases and newer systems
of work organization (such as lean
manufacturing) are changing the nature
of labor-intensive work, prevention of
MSDs will be more critical to protecting
older workers and maintaining
productivity.
This study will evaluate the efficacy
of two intervention strategies for
reducing musculoskeletal symptoms
and pain in the shoulder attributable to
overhead assembly work in automotive
manufacturing. These interventions are,
(1) an articulating spring-tensioned tool
support device that unloads from the
worker the weight of the tool that would
otherwise be manually supported, and,
(2) a targeted exercise program intended
to increase individual employees’
strength and endurance in the shoulder
and upper arm stabilizing muscle group.
As a primary prevention strategy, the
tool support engineering control
approach is preferred; however, a costefficient opportunity exists to
concurrently evaluate the efficacy of a
preventive exercise program
intervention. Both of these intervention
approaches have been used in the
Manufacturing sector, and preliminary
evidence suggests that both approaches
may have merit. However, high quality
evidence demonstrating their
effectiveness, by way of controlled
trials, is lacking. This project will be
conducted as a partnership between
NIOSH and Toyota Motors Engineering
& Manufacturing North America, Inc.
(TEMA), with the intervention
evaluation study taking place at the
Toyota Motor Manufacturing Kentucky,
Inc. (TMMK) manufacturing facility in
Georgetown, Kentucky. The prospective
intervention evaluation study will be
conducted using a group-randomized
controlled trial multi-time series design.
Four groups of 25–30 employees will be
established to test the two intervention
treatment conditions (tool support,
exercise program), a combined
intervention treatment condition, and a
control condition. The four groups will
be comprised of employees working on
two vehicle assembly lines in different
parts of the facility, on two work shifts
(first and second shift). Individual
randomization to treatment condition is
not feasible, so a group-randomization
(by work unit) will be used to assign the
four groups to treatment and control
conditions. Observations will be made
over the 24-month study period and
questionnaires will include the
Shoulder Rating Questionnaire (SRQ),
Disabilities of the Arm, Shoulder and
Hand (DASH) questionnaire, a
Standardized Nordic Questionnaire for
body part discomfort, and a Work
Organization Questionnaire. In addition
to the questionnaires a shoulder-specific
functional capacity evaluation test
battery will be administered at 90 and
210 days, immediately pre- and postintervention, to confirm the efficacy of
the targeted exercise program in
improving shoulder capacity.
In summary, this study will evaluate
the effectiveness of two interventions to
reduce musculoskeletal symptoms and
pain in the shoulder associated with
repetitive overhead work in the
manufacturing industry and the
associated research project will
disseminate the results of evidencebased prevention practices to the
greatest audience possible.
There is no cost to respondents other
than their time. The estimated
annualized burden is 236 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Number of
respondents
Form name
Number of
responses per
respondent
Average
burden per
response
(in hours)
mstockstill on DSK4VPTVN1PROD with NOTICES
Employees
Informed Consent Form .....................................................................
Consent of Photographic Image Release ..........................................
Physical Activity Readiness (PAR–Q) ................................................
Shoulder Rating Questionnaire ..........................................................
Disabilities of Arm Shoulder and Hand Dash (DASH) .......................
Standardized Nordic Questionnaire for Musculoskeletal Symptom
Instruments.
Work Organization Questionnaire ......................................................
VerDate Sep<11>2014
18:14 Nov 16, 2015
Jkt 238001
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
E:\FR\FM\17NON1.SGM
63
63
63
63
63
63
1
1
1
10
10
10
5/60
2/60
2/60
4/60
6/10
4/60
63
3
26/60
17NON1
71806
Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–29273 Filed 11–16–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–16–1019; Docket No. CDC–2015–
0102]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995.
This notice invites comment on
Integrating Community Pharmacists and
Clinical Sites for Patient-Centered HIV
Care. CDC is requesting a 3-year
approval for revision to the previously
approved project to administer a staff
communication questionnaire for
medical providers in order to determine
how and if the model program improves
patient outcomes through improved
communication and collaboration
between patients’ clinical providers and
pharmacists.
DATES: Written comments must be
received on or before January 19, 2016.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2015–
0102 by any of the following methods:
• Federal eRulemaking Portal:
Regulation.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS–
D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:14 Nov 16, 2015
Jkt 238001
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment
should be submitted through the
Federal eRulemaking portal
(Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS–D74, Atlanta,
Georgia 30329; phone: 404–639–7570;
Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
Proposed Project
Integrating Community Pharmacists
and Clinical Sites for Patient-Centered
HIV Care (OMB 0920–1019, expires 8/
31/2018)—Revision—National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Medication Therapy Management
(MTM) is a group of pharmacist
provided services that is independent
of, but can occur in conjunction with,
provision of medication. Medication
Therapy Management encompasses a
broad range of professional activities
and cognitive services within the
licensed pharmacists’ scope of practice
and can include monitoring prescription
filling patterns and timing of refills,
checking for medication interactions,
patient education, and monitoring of
patient response to drug therapy.
HIV-specific MTM programs have
demonstrated success in improving HIV
medication therapy adherence and
persistence. While MTM programs have
be shown to be effective in increasing
medication adherence for HIV-infected
persons, no MTM programs have been
expanded to incorporate primary
medical providers in an effort to
establish patient-centered HIV care. To
address this problem, CDC has entered
into a public-private partnership with
Walgreen Company (a.k.a. Walgreens
pharmacies, a national retail pharmacy
chain) to develop and implement a
model of HIV care that integrates
community pharmacists with primary
medical providers for patient-centered
HIV care. The model program will be
implemented in ten sites and will
provide patient-centered HIV care for
approximately 1,000 persons.
The patient-centered HIV care model
will include the core elements of MTM
as well as additional services such as
individualized medication adherence
counseling, active monitoring of
prescription refills and active
collaboration between pharmacists and
medical clinic providers to identify and
resolve medication related treatment
problems such as treatment
effectiveness, adverse events and poor
adherence. The expected outcomes of
the model program are increased
retention in HIV care, adherence to HIV
E:\FR\FM\17NON1.SGM
17NON1
]]>Agencies
[Federal Register Volume 80, Number 221 (Tuesday, November 17, 2015)]
[Notices]
[Pages 71804-71806]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-29273]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-16-0964]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Written comments and/or
suggestions regarding the items contained in this notice should be
directed to the Attention: CDC Desk Officer, Office of Management and
Budget, Washington, DC 20503 or
[[Page 71805]]
by fax to (202) 395-5806. Written comments should be received within 30
days of this notice.
Proposed Project
Interventions to Reduce Shoulder MSDS in Overhead Assembly (OMB No.
0920-0964 Exp. 04/30/2015)--Reinstatement--National Institute for
Occupational Safety and Health (NIOSH), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The mission of the National Institute for Occupational Safety and
Health (NIOSH) is to promote safety and health at work for all people
through research and prevention. Under Public Law 91- 596, sections 20
and 22 (Section 20-22, Occupational Safety and Health Act of 1970),
NIOSH has the responsibility to conduct research to advance the health
and safety of workers. In this capacity, NIOSH proposes to conduct a
study to assess the effectiveness and cost-benefit of occupational
safety and health (OSH) interventions to prevent musculoskeletal
disorders (MSDs) among workers in the Manufacturing (MNF) sector.
A reinstatement is necessary because there were significant delays
in implementing the tooling intervention in the intended work
processes. These delays were to a large degree due to business
conditions and were outside of the control of investigators. As result,
the study achieved approximately 50% of the original sample size
approved by OMB in the original ICR request. The reinstatement is
necessary to extend the duration of the ICR so that the additional
participants can enrolled and data collection can continue.
The U.S. Manufacturing sector has faced a number of challenges
including an overall decline in jobs, an aging workforce, and changes
in organizational management systems. Studies have indicated that the
average age of industrial workers is increasing and that older workers
may differ from younger workers in work capacity, injury risk, severity
of injuries, and speed of recovery (Kenny et al., 2008; Gall et al.,
2004; Restrepo et al., 2006). As the average age of the industrial
population increases and newer systems of work organization (such as
lean manufacturing) are changing the nature of labor-intensive work,
prevention of MSDs will be more critical to protecting older workers
and maintaining productivity.
This study will evaluate the efficacy of two intervention
strategies for reducing musculoskeletal symptoms and pain in the
shoulder attributable to overhead assembly work in automotive
manufacturing. These interventions are, (1) an articulating spring-
tensioned tool support device that unloads from the worker the weight
of the tool that would otherwise be manually supported, and, (2) a
targeted exercise program intended to increase individual employees'
strength and endurance in the shoulder and upper arm stabilizing muscle
group. As a primary prevention strategy, the tool support engineering
control approach is preferred; however, a cost-efficient opportunity
exists to concurrently evaluate the efficacy of a preventive exercise
program intervention. Both of these intervention approaches have been
used in the Manufacturing sector, and preliminary evidence suggests
that both approaches may have merit. However, high quality evidence
demonstrating their effectiveness, by way of controlled trials, is
lacking. This project will be conducted as a partnership between NIOSH
and Toyota Motors Engineering & Manufacturing North America, Inc.
(TEMA), with the intervention evaluation study taking place at the
Toyota Motor Manufacturing Kentucky, Inc. (TMMK) manufacturing facility
in Georgetown, Kentucky. The prospective intervention evaluation study
will be conducted using a group-randomized controlled trial multi-time
series design. Four groups of 25-30 employees will be established to
test the two intervention treatment conditions (tool support, exercise
program), a combined intervention treatment condition, and a control
condition. The four groups will be comprised of employees working on
two vehicle assembly lines in different parts of the facility, on two
work shifts (first and second shift). Individual randomization to
treatment condition is not feasible, so a group-randomization (by work
unit) will be used to assign the four groups to treatment and control
conditions. Observations will be made over the 24-month study period
and questionnaires will include the Shoulder Rating Questionnaire
(SRQ), Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire,
a Standardized Nordic Questionnaire for body part discomfort, and a
Work Organization Questionnaire. In addition to the questionnaires a
shoulder-specific functional capacity evaluation test battery will be
administered at 90 and 210 days, immediately pre- and post-
intervention, to confirm the efficacy of the targeted exercise program
in improving shoulder capacity.
In summary, this study will evaluate the effectiveness of two
interventions to reduce musculoskeletal symptoms and pain in the
shoulder associated with repetitive overhead work in the manufacturing
industry and the associated research project will disseminate the
results of evidence-based prevention practices to the greatest audience
possible.
There is no cost to respondents other than their time. The
estimated annualized burden is 236 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Employees
Informed Consent Form... 63 1 5/60
Consent of Photographic 63 1 2/60
Image Release.
Physical Activity 63 1 2/60
Readiness (PAR-Q).
Shoulder Rating 63 10 4/60
Questionnaire.
Disabilities of Arm 63 10 6/10
Shoulder and Hand Dash
(DASH).
Standardized Nordic 63 10 4/60
Questionnaire for
Musculoskeletal Symptom
Instruments.
Work Organization 63 3 26/60
Questionnaire.
----------------------------------------------------------------------------------------------------------------
[[Page 71806]]
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2015-29273 Filed 11-16-15; 8:45 am]
BILLING CODE 4163-18-P
